4
Changes in Ownership
Celldex Therapeutics, Inc. Filed Acc 0001179110-21-011251
SVP and CFO sold 9,500 shares at $42.00 ($399,000)
- SVP and CFO acquired 7,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates SVP and CFO | 2021-12-23 | Option exercise | +3,250 | $9.02 | $29,304 | 30,128 | D |
| Martin Samuel Bates SVP and CFO | 2021-12-23 | Option exercise | +3,750 | $2.78 | $10,425 | 33,878 | D |
| Martin Samuel Bates SVP and CFO | 2021-12-23 | Sale | −9,500 | $42.00 | $399,000 | 24,378 | D |
| Derivatives | |||||||
| Martin Samuel Bates SVP and CFO | 2021-12-23 | Option exercise · Incentive Stock Option (Right to Buy) | −3,250 | 9,530 | D | ||
| Martin Samuel Bates SVP and CFO | 2021-12-23 | Option exercise · Incentive Stock Option (Right to Buy) | −3,750 | 24,421 | D | ||
| Open-market sales · 9,500 sh · avg $42.00 · $399,000 | |||||||
Loading xslF345X03/edgar.xml…